Cell-type specific regulation of the human 11beta-hydroxysteroid dehydrogenase type 1 promoter

Archives of Physiology and Biochemistry

Volumn 113, Issue 3, 2007, Pages 110-115

  Andres, Janin ^a,b   Mai, Knut ^b   Möhlig, Matthias ^a,b   Weickert, Martin O ^a,b   Bumke Vogt, Christiane ^b   Diederich, Sven ^b   Pfeiffer, Andreas F H ^a,b   Bähr, Volker ^b   Spranger, Joachim ^a,b  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

11beta HSD1; C EBP; Promoter; Regulation

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; PRIMER DNA;

ADIPOSE TISSUE; ANIMAL; CELL STRAIN 3T3; CONFERENCE PAPER; CYTOLOGY; ENZYMOLOGY; GENETICS; HUMAN; LIVER; MOUSE; NUCLEOTIDE SEQUENCE; PROMOTER REGION; TUMOR CELL LINE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 3T3-L1 CELLS; ADIPOSE TISSUE; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; LIVER; MICE; PROMOTER REGIONS (GENETICS);

ANIMALIA; MURINAE; RENILLA; RENILLA LUCIFERASE;

EID: 35148818716     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450701531219     Document Type: Conference Paper

References (26)

1. Abdallah BM, Beck-Nielsen H, Gaster M. 2005. Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur J Clin Invest 35:627-34.
2. Altuna ME, Lelli SM, San Martin de Viale LC, Damasco MC. 2006. Effect of stress on hepatic 11beta-hydroxysteroid dehydrogenase activity and its influence on carbohydrate metabolism. Can J Physiol Pharmacol 84:977-84.
3. Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller DE, Wright SD, Thieringer R. 2001. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 276:12,629-35.
4. Dyer BW, Ferrer FA, Klinedinst DK, Rodriguez R. 2000. A noncommercial dual luciferase enzyme assay system for reporter gene analysis. Anal Biochem 282:158-61.
5. Eijken M, Hewison M, Cooper MS, de Jong FH, Chiba H, Stewart PM, Uitterlinden AG, Pols HA, van Leeuwen JP. 2005. 1 lbeta-Hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation. Mol Endocrinol 19:62131.
6. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Heintze U, Janke J, Luft FC, Sharma AM. 2004. Regulation of 11betaHSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 12:9-17.
7. Gout J, Tirard J, Thevenon C, Riou JP, Begeot M, Naville D. 2006. CCAAT/enhancer-binding proteins (C/EBPs) regulate the basal and cAMP-induced transcription of the human 11beta-hydroxysteroid dehydrogenase encoding gene in adipose cells. Biochimie 88:1115-24.
8. Grey A, Bolland M, Gamble G, Wattie D, Home A, Davidson J, Reid IR. 2007. The peroxisome-proliferatoractivated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305-10.
9. Jang C, Obeyesekere VR, Dilley RJ, Alford FP, Inder WJ. 2006. 11 Beta hydroxysteroid dehydrogenase type 1 is expressed and is biologically active in human skeletal muscle. Clin Endocrinol (Oxf) 65:800-5.
10. Kannisto K, Pietilainen KH, Ehrenborg E, Rissanen A, Kaprio J, Hamsten A, Yki-Jarvinen H. 2004. Overexpression of 11 {beta}-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: Studies in young adult monozygotic twins. J Clin Endocrinol Metab 89:4414-21.
11. Kolak M, Yki-Jarvinen H, Kannisto K, Tiikkainen M, Hamsten A, Eriksson P, Fisher RM. 2007. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab 92:720-4.
12. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CRW, Seckl JR, Mullins JJ. 1997. 11Beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94:14,924-9.
13. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. 2007. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669-80.
14. Lindsay RS, Wake DJ, Nair S, Bunt J, Livingstone DE, Permana PA, Tataranni PA, Walker BR. 2003. Subcutaneous adipose 11beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in pima indians and Caucasians. J Clin Endocrinol Metab 88:2738-44.
15. Mariniello B, Ronconi V, Rilli S, Bernante P, Boscaro M, Mantero F, Giacchetti G. 2006. Adipose tissue 11betahydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur J Endocrinol 155:435-41.
16. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. 2001. A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-70.
17. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, Seckl JR. 2001. Improved lipid and lipoprotein profile, hepatic insulin sensitivity and glucose tolerance in 11ß- hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276:41,293-300.
18. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR. 2004. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53:931-8.
19. Nakano S, Inada Y, Masuzaki H, Tanaka T, Yasue S, Ishii T, Arai N, Ebihara K, Hosoda K, Maruyama K, Yamazaki Y, Shibata N, Nakao K. 2007. Bezafibrate regulates the expression and enzyme activity of 11 {beta} -hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 292:1213-22.
20. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR. 2001. Tissue-specific dysregulation of Cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:1418-21.
21. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR. 2005. Increased in vivo regeneration of Cortisol in adipose tissue in human obesity and effects of the 1 lbetahydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone 3. Diabetes 54:872-9.
22. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. 1999. Cortisol metabolism in human obesity: impaired cortisone-→ Cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84:1022-7.
23. Teng CT, Pentecost BT, Chen YH, Newbold RR, Eddy EM, McLachlan JA. 1989. Lactotransferrin gene expression in the mouse uterus and mammary gland. Endocrinology 124:992-9.
24. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM. 2004. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocrine Rev 25:831-66.
25. Williams LJ, Lyons V, Wallace R, Seckl JR, Chapman KE. 1997. CCAAT/enhancer binding protein positively regulates the rat 11 beta-hydroxysteroid dehydrogenase type 1 promoter in liver cells. Biochem Soc Trans 25:235S.
26. Yang C, Bolotin E, Jiang T, Sladek FM, Martinez E. 2007. Prevalence of the initiator over the TATA box in human and yeast genes and identification of DNA motifs enriched in human TATA-less core promoters. Gene 389:52-65.